FIND
Diagnosis for all

2024 Activity Report

Driving diagnostic innovation in the face of an evolving global landscape

Leadership Message

Fostering innovation in diagnostics through product development and evidence generation is FIND's core mission.

Fostering innovation in diagnostics through product development and evidence generation is FIND's core mission. Increasingly, we are working with countries to increase their access to high-quality, reliable and affordable diagnostic tools at all levels of their healthcare systems, and especially at primary healthcare clinics.

In recent years, FIND has played a more consistent role in policy discussions, often acting as the sole advocate for testing.

Both through deliberate choice and evolving need, FIND has been positioned as the leader in global diagnostics. In 2024, the organization played a critical role in shaping global health policy, engaging key partners and governments to advance shared strategic priorities and elevate diagnostics as a cornerstone of universal health coverage. We also focused on strengthening ties with key stakeholders in the United States and Canada, while engaging with a range of advocacy coalitions such as the Global Health Technologies Coalition and the Global Health Council.

Building on previous engagement with the Indonesian and Indian G20 presidencies, FIND was invited to participate in the 2024 Brazilian G20 Health Track. Through sustained dialogue with Brazil's leadership, G20 Member States, and international organizations, FIND helped ensure that diagnostic-related priorities remained central to the agenda. This engagement has in turn led to a continued relationship with the South African presidency of the G20 in 2025.

FIND has continued to evolve as an organization, strengthening its position as the leading voice in diagnostics and sustaining its technical authority, with the trust of governments, donors, private sector companies, and civil society organizations.

Going forward, as FIND adopts a more country-driven approach transcending the traditional donor-driven PDP model, FIND will further strengthen its role as a trusted and equal partner in global health. This strategic pivot toward a country-driven approach is vital for fostering sustainable and equitable access to diagnostics worldwide.

The Board offers heartfelt thanks to the FIND team, and to all our partners, donors, and stakeholders across the world for your dedication and ongoing support.

DR AYOADE ALAKIJA
BOARD CHAIR

DR IFEDAYO ADETIFA
CHIEF EXECUTIVE OFFICER

Advancing the diagnostics agenda

In recent years, FIND has been strengthening its voice in policy discussions, often being the sole advocate for diagnostics. In 2024, FIND played a critical role in shaping global health policy, engaging key partners and governments to advance FIND's vision of 'Diagnosis For All' through the elevation of diagnostics as a cornerstone of universal health coverage and the key to global health security.

WORLD HEALTH ASSEMBLY (WHA) RESOLUTION – COMMITMENTS TRACKER

- A major milestone in 2023 was the adoption of the World Health Assembly (WHA) resolution on strengthening diagnostic capacity, which enabled countries to prioritize essential systems and resources to ensure universal access to testing. To mark its first anniversary, **FIND launched a Commitments Tracker during FIND's Diagnostics Day event on the sidelines of the WHA in 2024.**
- **The tracker is a public platform that enables global health stakeholders to pledge actions that will support Member States in implementing the resolution.** With commitments from 19 organizations to date, including development partners, civil society organizations and private sector companies, this initiative underscored the critical role of non-state actors in strengthening diagnostic capacity.

G20 ENGAGEMENT

- Building on previous engagement with the Indonesian and Indian G20 presidencies, **FIND was invited to participate in the 2024 Brazilian G20 Health Track.** Through sustained dialogue with Brazil's leadership, G20 Member States, and international organizations, FIND ensured that diagnostic-related priorities remained central to the agenda.
- **FIND's team had bilateral meetings with representatives from nine G20 countries, as well as 12 international organizations.** FIND also delivered 16 intervention statements and co-hosted a high-profile co-branded event with Africa CDC, the Drugs for Neglected Diseases Initiative (DNDi), the Pan American Health Organization (PAHO), and Unitaid, on regional production and manufacturing. The event provided key recommendations to the Brazilian Presidency on enhancing regional manufacturing and production efforts.

STRENGTHENED TIES WITH US & CANADA

- To strengthen ties with key stakeholders in the US and Canada, **FIND facilitated high-level engagements, effectively positioning itself as a global leader in diagnostics.** In Washington, D.C., FIND's leadership met with USAID, the President's Malaria Initiative, and the White House Office of Pandemic Preparedness. FIND also conducted a full day briefing on its work at the US Centres for Disease Control and Prevention (US CDC), organized by the National Centre for Emerging Zoonotic and Infectious Diseases.
- In Canada, **FIND co-hosted a virtual roundtable on women's health research and development (R&D)** with CEPI, Unitaid, and Results Canada, highlighting Canada's leadership in R&D and innovation; it also stressed the importance of developing and testing tools. Additionally, FIND submitted a brief to Canada's House of Commons Standing Committee on Foreign Affairs that outlined recommendations on Canada's approach to health engagement in Africa.

ANTIMICROBIAL RESISTANCE

- Ahead of the AMR Ministerial Conference in Jeddah in November 2024, **FIND led a session entitled "Deep Dive into Diagnostics – The Testing Case for AMR",** bringing together senior representatives from governments, multilateral bodies, and industry to emphasize the need for the integration of diagnostics into AMR strategies and National Action Plans (NAPs).
- **At the WHA, FIND co-hosted the launch of The Lancet Series on AMR** alongside One Health Trust, Africa CDC, AMR Action Fund, International Centre for Antimicrobial Resistance Solutions (ICARS), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Global AMR R&D Hub, and Infectious Diseases Society of America (IDSA).
- Later, **at the UNGA High-Level Meeting on AMR, FIND reinforced the importance of diagnostics** in a published statement and co-hosted a symposium with the same key partners along with the US CDC and the Gates Foundation, which focused on translating UNGA commitments into ensuring sustainable access to effective antibiotics.

UNITAID COLLABORATION

- As part of the Unitaid-funded DriveDx4TB project, **FIND collaborated closely with the Global TB Caucus to enable sustained advocacy for TB diagnostics.** This partnership involved engaging parliamentarians through parliamentary briefings, Caucus summits, media outreach, and coordinated efforts at national, regional and multilateral levels. FIND's new CEO also started meeting with the ambassadors and Ministers of Health at the Geneva Missions, to raise awareness about FIND and its work.
- In 2024, **FIND developed the first organizational framework for community and civil society engagement (CCSE)** and showcased our CCSE work at platforms such as the Unitaid Communities Delegation meeting in Mumbai.

OTHER ENGAGEMENTS

- At the World Health Summit 2024, FIND hosted an official side event, **100 Days Mission for diagnostics: vision and priorities for diagnostics pandemic preparedness.** The event helped increase understanding of the importance of diagnostics in pandemic preparedness.
- Throughout 2024, **FIND also engaged with a range of advocacy coalitions,** including the Global Health Technologies Coalition, Global Health Council, the Pandemic Action Network and the Global TB Caucus, among many others.

Transformation

FIND underwent significant structural changes in 2024.

The recruitment of Dr Ifedayo Adetifa as Chief Transformation Officer and CEO in August 2024 was the first step in addressing the leadership gaps following the departure of various executive members in 2023-24. Dr. Adetifa was followed by the hiring of key senior management positions, including the Head of External Affairs and Directors of Operations and Finance.

In addition to leadership changes in 2023 and 2024, the end of COVID-19 funding led to a significant drop in grant income. As a result, staffing levels were reduced across the organization, beginning in 2023. In addition to adapting costs to reduced revenues, this downsizing process provided an opportunity to refocus on the organization's core priorities and revise its business model to move from a top-heavy structure to a more balanced one, maximizing the value of its business activities.

As part of the transformation agenda, the organization initiated a realignment process to better focus FIND's resources on its core mission and enhancing its impact on the populations FIND seeks to serve. Ultimately, FIND's transformation agenda is aimed at delivering on its vision: a world where everyone, everywhere has access to affordable, quality diagnostics when and where they are needed.

KEY INITIATIVES IN ORGANIZATIONAL MANAGEMENT

- **The process of articulating the organization's 2025-2030 strategy is ongoing, with a launch planned once finalized.**
- **The revision of operational processes initiated in the last quarter of 2024 will facilitate the harmonization of our operations for better efficiencies and synergies.**
- **The strengthening of country offices and creation of regional hubs are critical to our strategic decision to be more country-centric in the work we do.**

These initiatives will promote the establishment of a global FIND and the decentralization of Geneva-based functions, enhancing efficiency and value for money.

Governance

There were changes to FIND's board membership in 2024. At the end of 2024, the board remained properly constituted with a membership of five (5) and continued to execute its statutory functions in governance and strategy.

The recruitment process for new board members will continue in 2025, focusing on enhancing diversity and representation from the countries where FIND is actively expanding its support, and the communities it serves.

FIND's Technical Expertise

FIND staff members published or contributed to almost 50 scientific articles in 2024 in peer-reviewed journals such as Biomed Central, PubMed, The Lancet, and the BMJ, as well as presenting posters or presentations at more than 35 professional conferences.

FIND LAUNCHED FOUR SEARCHABLE DIRECTORIES FOR:

1. **Molecular Point-Of-Care (POC):** this directory provides information on two classes of devices that enable decentralised molecular testing: near POC and true POC.
2. **Blood Culture Instruments:** this directory includes fully automated blood culture platforms that enable microbial growth and detection using blood culture bottles. These instruments facilitate the diagnosis and management of bloodstream infections at the hospital level.
3. **Blood Glucose Meters (BGMs):** this directory presents technical and practical information in standardized tables designed to inform the community by comparing various features. The list is not exhaustive but provides an overview of products from a number of manufacturers of different sizes.
4. **Continuous Glucose Monitoring (CGM):** this directory presents technical and practical information in standardized tables designed to inform the community by comparing various features.

FIND ALSO UPDATED THREE TEST DIRECTORIES:

1. **Neglected Tropical Diseases (NTDs):** this directory includes comprehensive landscapes of commercialized tests of relevance for various disease. The list increased with six additional NTDs included in 2024: visceral leishmaniasis, schistosomiasis, onchocerciasis, lymphatic filariasis, leprosy and mycetoma.
2. **Antimicrobial resistance (AMR):** this directory includes a pipeline of tests in development and commercialized tests of relevance in the context of antimicrobial use, including tests for pathogen identification and detection, measuring host responses, detection of resistance genes or gene products, and antimicrobial susceptibility testing. A minor update in 2024 revised the directory, with the addition of diagnostic tests targeting fungal infections.
3. **Diagnostic tests for selected outbreak-prone pathogens:** this directory currently includes commercialized tests for the identification, detection, and/or surveillance of 13 diseases. A major update in 2024 revised the directory, with 10 diseases receiving updates to their respective tests.

In 2024, FIND published policy briefs on diagnostics and climate change, and diagnostics and gender equity and social inclusion.

Impact of the FIND portfolio in 2024

VISCERAL LEISHMANIASIS

TUBERCULOSIS

MALARIA & FEVERS

HIV

COVID-19

EBOLA

HUMAN AFRICAN TRYPANOSOMIASIS (HAT)

40 million

FIND-supported diagnostic products distributed worldwide[1]

4 million

disability-adjusted life years (DALYs) averted

US$15 billion

in economic value from health gains

Driving innovation across the diagnostics value chain

Research and development



FIND advanced innovation in diagnostics by:

- **SUPPORTING 28 PIPELINE PRODUCTS** – a subset of FIND's full portfolio – through direct grants and technical assistance for product development. This included 15 in-vitro diagnostic (IVD) products, two digital tools and 11 non-diagnostic products.
- **PROVIDING SUPPORT TO AN ADDITIONAL 85 PRODUCTS** through pre-market feasibility studies, analytical and clinical studies, operational and implementation studies, and post-market performance evaluations for approval in countries.
- **COMPLETING THE DEVELOPMENT OF FOUR PRODUCTS,** including a rapid diagnostic test for yellow fever which is being transferred to the manufacturer diaTROPIX.
- **SUPPORTING 29 RESEARCH STUDIES ACROSS 22 COUNTRIES AND CONDUCTING 21 MARKET ASSESSMENTS,** including 15 clinical studies, seven operational and implementation research studies, and seven analytical performance evaluations.
- **DISTRIBUTING 2,610 SAMPLES** from the FIND Specimen Bank to accelerate diagnostic research and development.

Manufacturing

FIND strengthened local and regional manufacturing by:

- **AUDITING THE QUALITY MANAGEMENT SYSTEMS OF TWO IVD MANUFACTURERS** to ensure compliance with international standards.
- **INITIATING TECHNOLOGY TRANSFER OF A NEW HIV RAPID DIAGNOSTIC TEST (RDT)** from Bionote (a Korean manufacturer) to diaTROPIX, a project of the Institut Pasteur Dakar.
- **DELIVERING TWO CAPACITY BUILDING "BOOTCAMPS" IN INDONESIA** on "Keys to Successfully Bringing New Quality-assured IVD Products to Market" for **54 PARTICIPANTS FROM 34 MANUFACTURERS.**



Policy and regulation

FIND strengthened policy frameworks and regulatory pathways by:

- **SUPPORTING 11 COUNTRIES** to conduct diagnostic network optimization exercises.
- **INFLUENCING TB PREVENTION POLICY AND PRACTICE IN INDIA THROUGH THE JOINT EFFORT FOR ELIMINATION OF TUBERCULOSIS (JEET) PROJECT,** setting a precedent for data-driven policymaking and scalable TB prevention strategies.
- **DEVELOPING 10 TARGET PRODUCT PROFILES (TPPS)** for diagnostics addressing diabetes, bacterial meningitis, cholera, measles, rubella, HPV and TB.
- **PILOTING DIGITAL TOOLS FOR COMMUNITY HEALTH WORKERS IN KENYA AND RWANDA,** with results informing the development of a TB policy brief in Rwanda.
- **SUBMITTING A NEW YELLOW FEVER ANTIGEN-BASED RAPID DIAGNOSTIC TEST (RDT)** for regulatory approval.

Diagnostics are ultimately about people, with technology as the enabler – and this is reflected in FIND's work. In 2024, FIND's activities covered the full diagnostic value chain, from new product development to ensuring access to diagnostics when and where they are needed.

Procurement and supply management



FIND strengthened supply chains and improved access to essential diagnostics by:

- **STRENGTHENING PROCUREMENT AND SUPPLY CHAIN MANAGEMENT FOR GENOMIC SEQUENCING IN AFRICA** through actionable policy recommendations and advocacy and advisory notes developed at a joint FIND-Africa CDC workshop.
- Facilitating the distribution of **2.3 MILLION BLOOD GLUCOSE MONITORING STRIPS, 1,380 GLUCOSE METERS** and **9,870 HBA1C CARTRIDGES** to seven countries.

Capacity building and sustainability

FIND strengthened health systems and built local capacity by:

- **TRAINING MORE THAN 800 PRIVATE PROVIDERS IN INDIA** through the JEET 2.0 project, equipping them with the skills and knowledge necessary for effective TB prevention.
- **DEPLOYING THE DxGeoMap TOOL TO SUPPORT SEVERAL COUNTRY ANALYSES,** accompanied by a capacity-building workshop where 11 countries analyzed the accessibility of molecular TB diagnostics.
- **DELIVERING CLINICAL STUDY TRAINING PROGRAMMES ACROSS MULTIPLE COUNTRIES,** including Argentina, Bangladesh, Colombia, Kenya, Liberia, and South Africa.
- **PROVIDING TRAINING FOR MORE THAN 5,000 INDIVIDUALS** across a variety of diagnostic tools and services, including diagnostic network optimization, laboratory strengthening, good manufacturing practices, use of digital diagnostic tools, and more.

Awareness and advocacy



FIND amplified global awareness and drove advocacy for diagnostics by:

- **LAUNCHING THE COMMITMENTS TRACKER** to mark the first anniversary of the World Health Assembly resolution on strengthening diagnostic capacity. This public platform enables stakeholders to pledge actions supporting implementation of the resolution. To date, **19 ORGANIZATIONS HAVE MADE COMMITMENTS TO STRENGTHENING DIAGNOSTIC CAPACITIES.**
- **DEEPENING ENGAGEMENT WITH THE G20, JOINING THE HEALTH WORKING GROUP** and participating in the group's meetings during both the Brazilian and the South African presidencies. FIND delivered **16 INTERVENTION STATEMENTS** and co-hosted a high-profile co-branded event on regional production and manufacturing.
- **CHAMPIONING DIAGNOSTICS IN THE FIGHT AGAINST ANTIMICROBIAL RESISTANCE (AMR)** during the 2024 Year of AMR. FIND played a key advocacy role across major global platforms, including the WHA, the United Nations General Assembly (UNGA), the G20 and the AMR Ministerial Conference in Jeddah, where FIND led a session titled **"DEEP DIVE INTO DIAGNOSTICS – THE TESTING CASE FOR AMR",** to emphasize the need for the integration of diagnostics into AMR strategies and National Action Plans (NAPs).
- Hosting an official side event at the World Health Summit 2024, **"100 DAYS MISSION FOR DIAGNOSTICS: VISION AND PRIORITIES FOR DIAGNOSTICS PANDEMIC PREPAREDNESS".**
- **ORGANIZING THE SECOND DIAGNOSTICS DAY ON THE SIDELINES OF THE 2024 WORLD HEALTH ASSEMBLY,** bringing together speakers from the public sector, the private sector, and academia to discuss key topics in diagnostics.

Priorities and progress

I. Antimicrobial resistance

Antimicrobial resistance, or AMR, is one of the top three greatest threats to global health security, according to the World Health Organization (WHO). AMR can have severe consequences for both human and animal health if solutions are not found. FIND has been working to support access to diagnostics, which is a key step to ensuring that antibiotics are appropriately prescribed and used.

ADVOCACY

2024 was designated as the Year of AMR, and FIND played a key role in raising awareness across major global platforms, including the WHA, the United Nations General Assembly (UNGA), the G20, and the World Vaccine Congress, to highlight the critical role of diagnostics in combating AMR.

At the WHA, FIND co-hosted the launch of The Lancet Series on AMR alongside One Health Trust, Africa CDC, AMR Action Fund, International Centre for Antimicrobial Resistance Solutions (ICARS), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Global AMR R&D Hub ,and Infectious Diseases Society of America (IDSA.) Later, at the UNGA High-Level Meeting on AMR, FIND reinforced the importance of diagnostics in a published statement and co-hosted a symposium with the same key partners along with the US Centres for Disease Control and Prevention (US CDC) and the Gates Foundation, which focused on translating UNGA commitments into ensuring sustainable access to effective antibiotics.

The 4th High-Level Meeting on Antimicrobial Resistance was convened by Saudi Arabia in Jeddah in October, where FIND led a session entitled **"Deep Dive into Diagnostics – The Testing Case for AMR",** bringing together senior representatives from governments, multilateral bodies and industry to emphasize the need for the integration of diagnostics into AMR strategies and National Action Plans (NAPs).

TOOLS

FIND has undertaken development of several tools to diagnose and monitor AMR. Work was begun in 2024 on an AMR detection platform from Curetis, but this work is currently on hold pending resumption of funding.

Three digital tools were developed and implemented at the primary healthcare level in Kenya and Nepal. These tools are intended to support an antimicrobial stewardship programme in Makueni County Referral and Teaching Hospital in Kenya and surveillance of hospital-acquired infections in Kikuyu PCEA Hospital in Kenya and Paropakar Maternity and Women's Hospital in Nepal. The continued use of these tools will lead to the increased availability of quality data regarding AMR, supporting clinical decision-making for antimicrobial use and improving patient management. These tools are now available for use at the various hospitals, as end-user training has been completed.

CAPACITY BUILDING

In 2024, FIND continued to expand its training programmes through the **FIND Training Academy,** including the launch of a new course, "AMR Scorecard Assessors Training" which enrolled 10 participants from Indonesia and Zambia, combining online and in-person training.

TECHNICAL ASSISTANCE

- FIND led the development of the **National AMR Surveillance Report** and **antimicrobial stewardship guidelines in Kenya.**
- In **India,** an **AMR diagnostic capacity assessment** was conducted in 30 health facilities.
- FIND also developed the **Data Standards Playbook for AMR in Indonesia.**

II. Women's health

WOMEN'S HEALTH CONTINUES TO BE A SIGNIFICANT AREA OF WORK FOR FIND, FOCUSING ON THREE PRIORITIES:

- Conditions disproportionately affecting or presenting differently in women and girls
- Conditions unique to women and girls
- Self-care interventions

ADVOCACY

FIND co-hosted a virtual roundtable on women's health research and development (R&D) with CEPI, Unitaid, and Results Canada, highlighting Canada's leadership in R&D and innovation. The session also stressed the importance of developing and testing tools to address the specific health needs of women.

TOOLS

Because of stigma, cultural norms, and issues of availability, many women – particularly in LMICs – do not have access to this simple preventive test. **One strategy being investigated is at-home testing for HPV,** where women could access a simple kit from their pharmacy, collect a sample at home, and receive results rapidly.

A multi-country study was conducted in Bangladesh, Kenya, and South Africa to evaluate dry vs. wet transport methods for self-collected vaginal specimens for the detection of high-risk HPV DNA. The study aimed to enrol 1,148 women with abnormal cervical cancer screening results. The study enrolled 595 participants in 2024. Preliminary insights suggest that self-sampling could reduce cultural barriers and improve accessibility to HPV screening, particularly in resource-limited settings. The evidence generated will inform national HPV strategies and support the scale-up of self-collection methods. This was accompanied by the **Cervical Cancer Elimination training programme through the FIND Academy,** which trained 52 healthcare workers (HCWs) across the three countries.

One area of focus is cervical cancer, which is a form of cancer that has the potential to be eliminated with the right prevention strategies, such as widespread access to diagnostics for HPV (human papillomavirus), the primary cause of cervical cancer.

III. Regional manufacturing

Majority of the world's diagnostics are manufactured by a limited number of companies mostly in high-income countries while most of the world's diagnostic gaps exists for populations in low- and middle-income countries.

As the COVID-19 pandemic demonstrated, making diagnostics, treatments, and vaccines readily available in a short timeframe is crucial to national responses. In addition, globalization has meant that the specific health needs of low- and middle-income countries (LMICs) are frequently underserved, with diagnostic tests not adapted for use in LMICs.

FIND is supporting efforts to decentralize manufacturing so that every country has sustainable access to appropriate, affordable diagnostics, and remains firmly committed to helping countries shorten the distance between symptoms and solutions by supporting local manufacturing.

INSTITUT PASTEUR DAKAR - diaTROPIX

One example of this effort is the collaboration with the Institut Pasteur Dakar. In 2024, FIND continued this highly successful partnership which began in 2020 when FIND and Unitaid partnered to boost local production of COVID-19 rapid tests in LMIC settings. Institute Pasteur of Dakar was engaged after applying to an expression of interest in 2020 under the Access to COVID-19 Tools (ACT) Accelerator's Diagnostics Pillar, issued by FIND and Unitaid.

diaTROPIX is a non-profit RDT production platform based at Institut Pasteur Dakar in Senegal. It aims to improve access to quality diagnostics for neglected tropical diseases (NTDs) across Africa. diaTROPIX maintains a balanced product portfolio designed to address both NTD surveillance needs and financial sustainability through higher-demand regional tests, positioning itself as a crucial contributor to Africa's diagnostic manufacturing capacity and healthcare sovereignty.

With the end of the Covid pandemic, diaTROPIX was seeking to build long-term, robust relationships that would lead to a sustainable business model. **Working in collaboration with FIND and Unitaid, diaTROPIX has expanded their manufacturing capacity** and in December 2024 launched a new facility capable of producing 75 million diagnostic tests a year.

Initially, the facility will produce rapid diagnostic tests (RDTs) for HIV. FIND initiated the transfer of a new HIV RDT for professional use from Bionote, a Korean manufacturer, to diaTROPIX in response to the PEPFAR (United States President's Emergency Plan for AIDS Relief) call for HIV tests made in Africa.

A project was underway in 2024 to transfer technology to diaTROPIX in 2025 for the production of an antigen yellow fever test. The yellow fever NS1 Ag RDT made considerable progress in 2024, with development completed in partnership with DCN and successful technology transfer. The test is now pending final verification and validation before submission for regulatory approval.

IV. Clinical studies

In 2024, FIND supported 29 studies across 22 countries, including 15 clinical studies, seven operational and implementation research studies, and seven analytical performance evaluations, advancing the development and evaluation of diagnostic solutions for priority diseases. Some of the key projects are outlined below.

MPOX

In August 2024, WHO declared mpox to be a public health emergency of international concern (PHEIC) and the Africa Centres for Disease Control and Prevention (Africa CDC) also declared mpox to be a Public Health Emergency of Continental Security (PHECS). With just 12% of cases confirmed in the laboratory, this underscored the need for reliable diagnostics. FIND completed analytical and clinical evaluations of **Xpert® Mpox and STANDARD™ M10 MPX/OPX,** demonstrating high sensitivity and moderate specificity, making them promising near-POC tools for outbreak settings. However, mpox Ag-RDTs showed high specificity (100%) but poor sensitivity, highlighting the urgent need for improved rapid diagnostics.

LASSA VIRUS

Similarly, clinical evaluations of Lassa virus (LASV) RDTs and PANDAA LASV assays (unpublished data) showed low sensitivity and specificity, emphasizing the need for better tools to enhance early detection and outbreak control, particularly in West Africa. **FIND's work has strengthened laboratory capacity at multiple sites,** enhancing preparedness for future diagnostic evaluations and clinical trials, which is critical when responding to emerging infectious disease threats.

TB

In the FEND-TB consortium, **44 new technologies were reviewed,** with eight advancing to clinical evaluations in 2024. Overall, across the three studies investigating adults, drug-resistant (DR)-TB and children, **FIND enrolled more than 1,000 participants** in Moldova, Peru, South Africa, Uganda, and Viet Nam. In the **DriveDx4TB study,** three technologies (Ustar Portnat, Ustar Multnat and SD Biosensor) were selected for analytical laboratory assessments. If successful, they will advance to clinical trial evaluations later in 2025.

HPV

A multi-country study was conducted in Bangladesh, Kenya, and South Africa to evaluate dry vs. wet transport methods for self-collected vaginal specimens for the detection of high-risk human papillomavirus (HPV) DNA. The study aimed to enrol 1148 women with abnormal cervical cancer screening results. The study enrolled 595 participants in 2024.

Preliminary insights suggest that self-sampling could reduce cultural barriers and improve accessibility to HPV screening, particularly in resource-limited settings. The evidence generated will inform national HPV strategies and support the scale-up of self-collection methods. Additionally, an analytical validation study was initiated to assess a POC candidate assay for iron deficiency anaemia. However, this study did not progress beyond protocol development.

DIABETES

The Access to CGMs for Equity in Diabetes Management (ACCEDE) team published a protocol for a three-arm pragmatic randomized controlled trial of continuous glucose monitoring (CGM) devices in individuals with type 1 diabetes in **South Africa** and **Kenya**. In South Africa, 246 participants were enrolled, and qualitative data collection was initiated to capture their experiences. Serious adverse events (SAEs) were closely monitored and reviewed by FIND's Medical Review Board. In Kenya, challenges led to a restructuring of the study, which will be implemented in 2025.

HIV & HEPATITIS

The LIVES study of multiplex self-testing for HIV, hepatitis B and hepatitis C among key populations was designed as a mixed-methods study. In 2024, data collection and analysis were completed, and preliminary results were presented at a **FIND-WHO Technical Consultation in November 2024.** A scientific publication is planned for 2025, and results will be presented at the 23rd European Meeting on HIV & Hepatitis (4-6 June).

SCHISTOSOMIASIS

FIND conducted a multi-country field evaluation of a prototype Ag-RDT for schistosomiasis monitoring and evaluation, developed by FIND and partners. The study enrolled more than **1,500 participants** across three sites in Kenya (Kenya Medical Research Institute) and two sites in the Philippines (University of East Ramon Magsaysay Memorial Medical Centre). This evaluation used a composite reference standard to assess the clinical performance of the Ag-RDT for detecting Schistosoma haematobium, S. mansoni, and S. japonicum. The data analysis is ongoing and will determine whether the test is fit-for-purpose as per the WHO target product profile (TPP).

CAPACITY BUILDING

In addition to the clinical studies themselves, clinical study training programmes were delivered across multiple countries.

- **The ACCEDE study in South Africa** trained HCWs in electronic data capture, protocol adherence, and study procedures, with 65 participants.
- **The Cervical Cancer Elimination programme** trained 52 HCWs in **Bangladesh, Kenya,** and **South Africa.**
- **The Diabetes Quality Assurance project in Colombia** included training for site staff in study procedures and documentation, involving 12 participants.
- Additionally, FIND conducted sessions on cost-effectiveness studies in **Argentina,** Chagas disease RDT evaluation in Argentina, and laboratory training in **Liberia** under **Outbreak Preparedness initiatives.**
- **In Kyrgyzstan and Indonesia,** FIND trained six community health workers in self-testing for HIV and hepatitis among people who inject drugs.
- The **FEND project** held multiple training sessions in **Moldova, Peru,** and **Viet Nam,** including training in protocols, laboratory manual updates, and Good Clinical Practice (GCP) guidelines, reaching more than 50 participants.

JEET 2.0

A Transformative Approach to Tuberculosis Prevention in India

Tuberculosis (TB) remains a significant public health threat in India, with latent TB infection affecting over 50% of household contacts in high-incidence areas.

Since 5-10% of infected individuals progress to active TB, early detection and treatment of TB are critical to India's goal of eliminating TB. The Joint Effort for Elimination of Tuberculosis (JEET) 2.0 (2021-24) supported by the Global Fund was launched to proactively screen and initiate TB preventive therapy (TPT) for household contacts of persons with TB, reducing the disease transmission burden and preventing future TB cases.

The Innovative Approach JEET 2.0 introduced a two-pronged strategy to tackle TBI:

JEET took an innovative approach to the problem of missing or undiagnosed TB cases through a two-pronged approach: "Screen & Treat," followed by "Screen, Test & Treat."

Initially, household contacts of TB patients were screened and evaluated for active TB before initiating TPT (Screen & Treat). Any household contacts who were asymptomatic then underwent a blood test (IGRA) to confirm an active infection before starting treatment, making TPT more targeted in resource-constrained settings and resource-efficient.

Additionally, JEET 2.0 was a pioneer in scaling up the 3HP regimen - a shorter, safer, and more effective TPT regimen requiring just 12 weekly doses over three months. This resulted in better adherence and treatment completion rates. The project operated across 28 districts in Andhra Pradesh, Telangana, Karnataka, and Punjab, with technical assistance extended to Odisha.

KEY STEPS IN THE PROJECT IMPLEMENTATION INCLUDED:

- **More than 400,000 household contacts of TB patients were screened; of these, 260,000 were initiated on TPT.**
- **800+ private providers were brought into the programme through targeted workshops and training sessions.**
- **Mobile screening vans, video consultations, and SMS follow-ups ensured coverage of hard-to-reach populations, including migrant workers and tribal communities.**

As a result of these targeted and innovative measures, 95% of those on 3HP completed their treatment, demonstrating a clear preference among those infected for shorter regimens.

Among contacts who completed TPT, only 0.23% developed active TB, confirming the long-term effectiveness of preventive therapy in reducing risk.

The National Tuberculosis Elimination Program (NTEP) integrated the lessons learned from the JEET 2.0 project into national strategy and then procured 133 million 3HP tablets to enable wider adoption of the JEET approach.

Four out of the five states involved in the project have integrated TBI testing into their domestically funded implementation plans for TPT initiatives, expanding beyond JEET 2.0's initial scope. The project also underscored the importance of effectively ruling out active TB before initiating TPT among vulnerable populations such as household contacts in highly endemic areas.

This approach also helped in diagnosing "sub-clinical TB," which is an early stage of the disease when the individuals are still asymptomatic. Effective implementation of TPT can further accelerate the reduction of TB incidence in India and globally.

JEET 2.0 has demonstrated a scalable, innovative model for tackling latent TB infection, contributing significantly to India's TB elimination goals.

By combining targeted screening, cutting-edge treatment regimens, and robust stakeholder engagement, the project has set a benchmark for TB prevention efforts in resource-limited settings. JEET 2.0's success has laid the groundwork for sustainable TB prevention efforts.

Diagnostics Day 2024

FIND hosted its second Diagnostics Day on the sidelines of the World Health Assembly, building on the success of the 2023 event.

The agenda explored critical topics in diagnostics, from integrated care to the 100 Days Mission, climate change, women's health, and the WHA Resolution on diagnostics.

Key experts from FIND were joined by global health leaders from the Global Fund, the Africa CDC, WHO, Global Coalition of TB Advocates, CITAMPlus, Indonesia's Ministry of Health, the White House, Drugs for Neglected Diseases (DNDi), Africa Public Health Foundation, and the Clinton Health Access Initiative, among others. Full recordings of the day's sessions can be found on the FIND website.

2025–2030 Strategy

The development of a new strategy was initiated in 2023 and continued in 2024. However, a rapidly shifting development and funding landscape – including the shared post-COVID19 financial contraction in the sector – as well as organizational changes taking place as part of a transformation process at FIND have meant that this strategy remained under development in 2024.

Thank you to all our donors and partners

- African Society of Laboratory Medicine (ASLM)
- Boston University
- Centre for Infectious Disease Research in Zambia (CIDRZ)
- Coalition for Epidemic Preparedness Innovations (CEPI)
- CRDF Global
- Department for Health and Social Care
- Department of Foreign Affairs and Trade (DFAT), Government of Australia
- Department of Foreign Affairs, Trade & Development of Canada
- Drugs for Neglected Diseases initiative (DNDi)
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- European Union
- Federal Ministry of Economic Cooperation and Development (BMZ), Government of Germany
- Federal Ministry of Education and Research (BMBF), Government of Germany
- Foundation to Promote Open Society
- Fundação para o Desenvolvimento Científico e Tecnológico em Saúde, Brazil
- Fundación Anesvad
- German Development Bank (KfW)
- Global Antimicrobial Resistance Research Innovation Fund (GAMRIF)
- Global Health Innovative Technology Fund (GHIT)
- Gordon and Betty Moore Foundation (GBMF)
- Government of Kuwait
- Government of Portugal
- International Committee of the Red Cross (ICRC)
- JHPIEGO
- JSI Research & Training
- Ministry of Foreign Affairs of the Netherlands (DGIS)
- MoH Mongolia
- Patrick J. McGovern Foundation
- Republic and Canton of Geneva
- Research Investment in Global Health Technology Fund (RIGHT Fund)
- Resolve to Save Lives
- Swiss Agency for Development & Cooperation (SDC)
- Swiss TPH
- The Bill & Melinda Gates Foundation
- The END Fund
- The Foreign, Commonwealth & Development Office (FCDO), UK Government
- The Gavi Alliance
- The Global Fund to Fight AIDS, Tuberculosis and Malaria
- The Leona M. and Harry B. Helmsley Charitable Trust
- The World Bank
- UNITAID
- United Nations Office for Project Services (UNOPS)
- United States Agency for International Development (USAID)
- University of New South Wales Sydney (UNSW Sydney)
- US Centers for Disease Control and Prevention (CDC)
- US National Institutes of Health (NIH)
- Wellcome Trust
- World Health Organization (WHO)

FIND audit report 2024

FIND
Diagnosis for all

Activity report 2024

Chemin du Pommier 40
1218 Grand-Saconnex,
Switzerland

www.finddx.org